3.1000
+0.2000
+(6.90%)
At close: 4:25:23 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
239,868.0000
194,874.0000
120,448.0000
87,616.0000
69,252.0000
Cost of Revenue
173,414.0000
150,688.0000
91,934.0000
64,517.0000
39,531.0000
Gross Profit
66,454.0000
44,186.0000
28,514.0000
23,099.0000
29,721.0000
Operating Expense
192,267.0000
170,352.0000
157,132.0000
141,663.0000
121,952.0000
Operating Income
-125,813.0000
-126,166.0000
-128,618.0000
-118,564.0000
-92,231.0000
Net Non Operating Interest Income Expense
-10,922.0000
-6,993.0000
-9,303.0000
-8,781.0000
-8,662.0000
Pretax Income
-133,478.0000
-106,684.0000
-137,390.0000
-126,464.0000
-102,091.0000
Net Income Common Stockholders
-133,477.0000
-106,683.0000
-137,389.0000
-126,463.0000
-102,090.0000
Diluted NI Available to Com Stockholders
-133,477.0000
-106,683.0000
-137,389.0000
-126,463.0000
-102,090.0000
Basic EPS
-0.33
-0.27
-0.37
-0.35
-0.31
Diluted EPS
-0.33
-0.27
-0.37
-0.35
-0.31
Basic Average Shares
406,905.5000
395,081.0000
374,737.0000
357,831.0000
333,650.0000
Diluted Average Shares
406,905.5000
395,081.0000
374,737.0000
357,831.0000
333,650.0000
Total Operating Income as Reported
-117,600.0000
-102,529.0000
-128,618.0000
-118,565.0000
-92,021.0000
Rent Expense Supplemental
--
4,493.0000
3,946.0000
2,609.0000
1,433.0000
Total Expenses
365,681.0000
321,040.0000
249,066.0000
206,180.0000
161,483.0000
Net Income from Continuing & Discontinued Operation
-133,477.0000
-106,683.0000
-137,389.0000
-126,463.0000
-102,090.0000
Normalized Income
-141,688.0000
-130,320.0000
-137,389.0000
-126,463.0000
-102,242.0000
Interest Income
563.0000
550.0000
651.0000
613.0000
553.0000
Interest Expense
11,485.0000
7,543.0000
9,954.0000
9,394.0000
9,215.0000
Net Interest Income
-10,922.0000
-6,993.0000
-9,303.0000
-8,781.0000
-8,662.0000
EBIT
-121,993.0000
-99,141.0000
-127,436.0000
-117,070.0000
-92,876.0000
EBITDA
-83,396.0000
-62,728.0000
-97,024.0000
-87,720.0000
-66,110.0000
Reconciled Cost of Revenue
173,414.0000
150,688.0000
91,934.0000
64,517.0000
39,531.0000
Reconciled Depreciation
38,597.0000
36,413.0000
30,224.0000
29,350.0000
26,766.0000
Net Income from Continuing Operation Net Minority Interest
-133,477.0000
-106,683.0000
-137,389.0000
-126,463.0000
-102,090.0000
Total Unusual Items Excluding Goodwill
8,211.0000
23,637.0000
--
--
152.0000
Total Unusual Items
8,211.0000
23,637.0000
--
--
152.0000
Normalized EBITDA
-91,607.0000
-86,365.0000
-97,024.0000
-87,720.0000
-66,262.0000
12/31/2020 - 12/2/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
PCIB.OL PCI Biotech Holding ASA
1.2420
-0.64%
GUARD.ST Guard Therapeutics International AB (publ)
21.00
-3.67%
PHAL.ST PharmaLundensis AB
1.0000
-10.71%
SIMRIS-B.ST Simris Group AB (PUBL)
0.0806
-6.71%
COMBI.ST CombiGene AB (publ)
2.4200
0.00%
2CUREX.ST 2cureX AB (publ)
0.4200
+16.67%
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.4920
+1.44%
CMOTEC-B.ST Scandinavian ChemoTech AB (publ)
1.1300
+2.73%
QUIA.ST Quia Pharma AB (publ)
0.0077
-13.48%
CRNA.OL Circio Holding ASA
0.6960
-1.42%